# Baldwin

Type: Company (BWIN)

Source: GetYourBrief — https://getyourbrief.com/entity/baldwin
Canonical HTML page: https://getyourbrief.com/entity/baldwin

## Timeline

- **2026**: NDA Submission — Planned submission of paltusotine New Drug Application to the FDA.
- **2026**: Phase 3 Initiation — Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
- **2025-Q4**: Earnings Call — Management confirms commercial readiness and pipeline acceleration.
- **2025-Q3**: PATHFNDR-2 Success — Completion of Phase 3 trial for paltusotine in acromegaly with positive results.

## Recent coverage (2 stories, network-wide)

### Crinetics Signals Commercial Readiness as Lead Candidates Near FDA Submission
2026-02-27 01:34:00 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
Full story: https://getbiobrief.com/story/crinetics-crnx-q4-2025-earnings-pipeline-analysis

### Q4 2025 Earnings: Precision Diagnostics and Endocrine Innovation Drive Growth
2026-02-27 01:33:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Full story: https://gethealthbrief.com/story/q4-2025-healthcare-earnings-crinetics-mdxhealth-baldwin

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.